A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Subjects With Major Depressive Disorder
Phase of Trial: Phase I
Latest Information Update: 03 Jul 2017
At a glance
- Drugs JNJ 54175446 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 27 Jun 2017 Status changed from recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 20 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.